MYRIAD GENETICS, INC. Payments of Financing Costs
MYRIAD GENETICS, INC. (MYGN) reported Payments of Financing Costs of $8.40 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2025-11-04
- 2025-09-30: Payments of Financing Costs 9 month $8.40M.
- 2024-09-30: Payments of Financing Costs 9 month $0.00.
| Period end | Payments of Financing Costs 9 month |
|---|---|
| 2025-09-30 | $8.40M 10-Q · filed 2025-11-04 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |